Top Stock to Buy #4 – DaVita HealthCare Partners (DVA)
DaVita HealthCare Partners (NYSE:DVA) is a provider of dialysis services for patients suffering from chronic kidney failure. It serves 142,000 people through a network of 1,809 dialysis centers.
On Dec. 20, JPMorgan Chase (NYSE:JPM) initiated coverage of DVA with an “overweight” rating and target of $125. Analysts have estimated earnings of $6.17 in 2012 and $7.38 in 2013.
The stock is in a bull market with support at its advancing bullish support line at just under $100. The stock advanced last year on a series of “step-ups” — a pattern associated with powerful long-term bullish trends. Traders could expect a quick run to $120, but long-term investors could see much higher prices. Buy DVA at the market.